Table 3.

Documented adverse events.

	Any Grade, (n/%)	≥Grade 3, (n/%)	Leading to Any Treatment Discontinuation (n/%)	Leading to Death, (n/%)
Bleeding events	20 (30.3)	18 (27.3)	11 (16.7)	3 (4.5)
Gastrointestinal bleeding Variceal bleeding	14 (21.2) 7 (10.6)	14 (21.2) 7 (10.6)	6 (9.1) 5 (7.5)	1 (1.5)
Subarachnoidal hemorrhage	2 (3.0)	2 (3.0)		2 (3.0)
Epistaxis	4 (6.0)	2 (3.0)
Worsening of renal function	10 (15.2)	8 (12.1)
Acute kidney failure	7 (10.6)	7 (10.6)	1 (1.5)
Acute on chronic kidney failure	1 (1.5)	1 (1.5)	1 (1.5)
Ascites	8 (12.1)	6 (9.1)	1 (1.5)
Pruritus	6 (9.1)
Diarrhea	5 (7.6)	2 (3.0)
Rash	4 (6.1)
Fatigue	4 (6.1)
Hyponatremia	3 (4.5)	1 (1.5)
Arterial hypertension	3 (4.5)
Ulcus lower extremities	3 (4.5)	1 (1.5)
Acute on chronic liver failure	2 (3.0)	2 (3.0)	1 (1.5)
Hepatic encephalopathy	2 (3.0)	2 (3.0)
Allergic reaction	2 (3.0)	1 (1.5)	1 (1.5)
Nausea	2 (3.0)
Emesis	1 (1.5)
Cholangitis	1 (1.5)	1 (1.5)	1 (1.5)
Pyrexia	1 (1.5)	1 (1.5)
Transient ischemic attack	1 (1.5)	1 (1.5)	1 (1.5)
Pulmonary embolism	1 (1.5)	1 (1.5)	1 (1.5)
Flare of autoimmune disease	1 (1.5)
Insomnia	1 (1.5)
Hyperbilirubinemia	1 (1.5)		1 (1.5)
Spontaneous bacterial peritonitis	1 (1.5)	1 (1.5)
Cough	1 (1.5)
Hyperkalemia	1 (1.5)
Hoarseness	1 (1.5)
Vasculitis	1 (1.5)
Anemia	1 (1.5)	1 (1.5)
Proteinuria	1 (1.5)
Edema	1 (1.5)
Worsening of heart failure	1 (1.5)
Stomatitis	1 (1.5)
Nephritis	1 (1.5)
Dry skin	1 (1.5)
Immune checkpoint-inhibitor hepatitis (ICI)	1 (1.5)	1 (1.5)	1 (1.5)
Esophageal candidiasis	1 (1.5)	1 (1.5)	1 (1.5)
Urogenital abscess	1 (1.5)	1 (1.5)	1 (1.5)